TABLE 2.
Peptidomimetic therapeutics mentioned in this review; primary function and target organ are indicated for each compound
| Target organ (indicated by number) | Peptidomimetic | Function |
|---|---|---|
| 1 | Pramlintide | Analog of amylin to treat T1DM and T2DM |
| 2 | Saralasin | Angiotensin II receptor agonist to reduce hypertension |
| 3 | Icatibant | Bradykinin 2 receptor antagonist to treat acute attacks of hereditary angioedema |
| 4 | Ziconotide | Blocks N-type voltage-gated calcium channels to treat chronic pain |
| 5 | Cyclosporine | Interferes with T cell activity to induce immunosuppression |
| 6 | Eptifibatide | Inhibits glycoprotein IIb/IIIa inhibitor to prevent blood clots |
| 7 | Vasopressin/desmopressin/terlipressin | Regulates plasma osmolality, cardiovascular, and brain functions |
| 8 | Linaclotide | Agonist that mimics guanylin and uroguanylin to treat chronic idiopathic constipation and constipation-predominant irritable bowel syndrome |
| 9 | Carbetocin | Agonist of peripheral oxytocin receptors to treat postpartum hemorrhage and bleeding |
| 10 | Daptomycin | Binds to Gram-positive bacterial membranes to inhibit growth |
| 11 | Afamelanotide | Analog of α-MSH to treat erythropoietic protoporphyria |